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Introduction
Pulmonary nodules present a unique challenge for radi-
ologists which includes the detection of malignancy and
identification of benign disease, recommending the appro-
priate procedures to avoid unnecessary thoracotomy, and
ensuring that excessive radiation from follow-up
computed tomography (CT) examinations is kept to a
minimum. Although seasoned radiologists can use an
approach based on their extensive experience, in this era
of evidence-based medicine, guidelines have been estab-
lished that include both radiologic and clinical factors in
an integrated fashion. Such guidelines have been
developed by the Fleischner Society, first in 2005, for the
management of small pulmonary nodules detected on CT
scans, and then, in 2013, for the management of sub-solid
nodules [1].
For incidentally detected solitary nodules, these guide-
lines integrate elements as individual risk factors (via
pre-test probability), with lesion size, growth rate, and
morphology, based on imaging characteristics. Relevant
risk factors to consider in the evaluation of pulmonary
nodules are smoking history and patient age. Patients
with a substantial smoking history and over 40 years of
age are defined as high-risk patients, whereas low-risk
patients are those with a negligible smoking history and
no other known risk factors, and who are below 40 years
of age.
Based on the Fleischner Society recommendation [1],
lesions less than 4 mm do not require any further inva-
sive or non-invasive measures or evaluations. However,
lesions with a diameter of more than 8mm should be
evaluated with either follow-up CT scans, including
dynamic, contrast-enhanced scans, positron emission
tomography (PET)-CT, and biopsy. For lesions that fall
between the 4 mm and 8 mm size, CT follow-up with a
limited number of scans is recommended.
Sub-solid nodules are often found during screening stu-
dies or incidentally on CT scans. They are characterized
by their appearance as rounded areas of increased attenua-
tion, and a homogeneous or heterogeneous texture.
Sub-solid nodules can be subdivided according to their
composition: non-solid lesions that consist of ground-glass
opacity only; and part solid lesions that contain both
ground-glass and soft tissue elements.
Sub-solid nodules can regress, persist, or grow. Small
persistent non-solid nodules are often atypical adenoma-
tous hypoplasia (AAH) and focal fibrosis, whereas
non-solid and part-solid nodules that increase in size
typically indicate malignancy, which can include adeno-
carcinoma in situ (AIS), minimally invasive adenocarci-
noma (MIA), and invasive adenocarcinoma, as well as
lympho-proliferative disease. How these lesions develop
has not been entirely elucidated as yet, but it seems that
a small percentage of ground-glass opacities (AAH)
develop into larger lesions that can eventually comprise
solid components due to invasion and alveolar collapse
[2]. In any case, radiologically, an increase in lesion den-
sity, growth, or the development of solid portions are all
indicative of malignancy.
CT analysis and surveillance of sub-solid nodules is the
modality of choice for the identification of malignant
lesions. The primary factor is nodule size. While lesions
less than 5 mm in diameter are usually AAHs, lesions
greater than 15 mm is size are malignant, and are typically
MIAs and invasive adenocarcinomas. Generally, a dia-
meter of more than 8 mm is indicative of malignancy.
Another important indicator of malignancy is lesion
growth. The growth of the lesion may affect either the
ground-glass or the solid components, or both. Volume
doubling times of AIS and MIAs are much longer,
compared to invasive adenocarcinomas and squamous cell
lesions.
Morphologically, the presence of lobulated borders, air
bronchograms and bubble-like lucencies, and the develop-
ment of solid portions in pure ground-glass abnormalities
are all indicative of malignancy. Lesion morphology is
closely related to prognosis. Nodules with an increasing
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percentage of solid components represent a poorer
prognosis, but, for patients with pure ground-glass
abnormalities or those with only a small area of a solid
component, the survival rate after lesion resection is 100%.
The Fleischner Society management guidelines [2] for
sub-solid lesions recommend that part solid nodules,
especially those that persist or grow in size, mandate
further evaluation and monitoring, and typically, require
surgical resection. Smaller lesions, with a negligible area
of solid components, can be managed with follow-up
CT scans.
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